Versartis, Inc. (VSAR) Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results
6/24/2014 8:33:49 AM
CHICAGO, June 23, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today presented positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD). These results are being presented by George Bright, MD, Versartis Vice President of Clinical Development, during the clinical poster session, "Growth and GH: Diagnostic Issues and Treatment" from 1:00 – 3:00 p.m. CDT today at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by